RTP Mobile Logo
Oncology Grand Rounds Series: Part 6 — Emerging Strategies in Non-Small Cell Lung Cancer
Released June 2019

Video proceedings from the sixth in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Ms Kelly EH Goodwin, Dr Joel W Neal, Ms Judy Pagtama and Dr Anne S Tsao. (Video Program)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

    Lung cancer is a devastating disease with a broad-reaching impact on public health as it accounts for 14% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. In the year 2019, it is estimated that approximately 228,150 individuals will be diagnosed with cancer of the lung and bronchus. Despite the many advances over the past few decades, death rates attributable to lung cancer have remained relatively unchanged. Today, many are optimistic that these trends have already started to change as recent research advances in oncology have led to the FDA approval of multiple biologic agents and immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC). With the emergence of many pivotal data sets and the investigation of other novel agents potentially poised to further disrupt traditional management algorithms, educational needs in the optimal management of NSCLC have never been greater.

    It is clear that many of the educational needs related to the care of patients with lung cancer are relevant specifically to the practicing medical oncologist directly responsible for therapeutic decision-making. However, the overall importance of the oncology nurse should not be diminished, as prospective and retrospective patient-level research has shown that oncology nurses play an integral role in the successful delivery of systemic anticancer therapy and in the preservation of the physical and psychosocial well-being of patients. These video proceedings from the final part of a 6-part integrated CNE curriculum originally held at the 2019 ONS Annual Congress feature discussions with leading lung cancer investigators and their nursing counterparts about actual patient cases and recent therapeutic advances and emerging strategies in the management of NSCLC.

    By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with lung cancer.


    • Review the recent FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
    • Review recent FDA approvals and other therapeutic advances related to the long-term management of metastatic NSCLC with an EGFR tumor mutation, and discern how this information should be applied to current off-protocol patient care.
    • Appreciate available clinical trial data with and the current role of anti-PD-1/PD-L1 antibodies in combination with chemotherapy and/or anti-angiogenic agents as first-line therapy for patients with metastatic NSCLC.
    • Educate patients about the side effects associated with recently approved therapies for NSCLC, and provide preventive strategies to reduce or ameliorate these toxicities.
    • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with NSCLC to optimize clinical and quality-of-life outcomes.

    Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    CNE credit is no longer available for this issue

    CNE credit is no longer available for this issue

    This CNE activity consists of a video component.
    CNE credit is no longer available for this issue

    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Kelly EH Goodwin, MSN, RN, ANP-BC
    Thoracic Cancer Center, Massachusetts General Hospital
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Joel W Neal, MD, PhD
    Assistant Professor of Medicine
    Division of Oncology
    Stanford Cancer Institute
    Stanford University
    Stanford, California

    Advisory Committee and Consulting Agreements: Ariad Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Genentech, Jounce Therapeutics Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Ariad Pharmaceuticals Inc, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech, Merck, Nektar, Novartis, Roche Laboratories Inc, Takeda Oncology.

    Judy Pagtama, RN, MSN, FNP-C
    Nurse Practitioner
    Stanford Cancer Institute
    Stanford, California

    No relevant conflicts of interest to disclose.

    Anne S Tsao, MD
    Director, Mesothelioma Program
    Director, Thoracic Chemo-Radiation Program
    Department of Thoracic/Head and Neck Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Ariad Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, Huron, Lilly, Merck, Novartis, Roche Laboratories Inc, Seattle Genetics, SELLAS Life Sciences, Takeda Oncology; Contracted Research: Ariad Pharmaceuticals Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Epizyme, Genentech, Lilly, Merck, Polaris Group, Seattle Genetics, Takeda Oncology; Data and Safety Monitoring Board/Committee: Xcovery.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RTP CNE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: June 2019
    Expiration date: June 2020

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):